Levocarnitine for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether adding levocarnitine to standard chemotherapy can better protect the liver in people with certain types of leukemia and lymphoma. Levocarnitine, a natural nutrient, may help reduce liver damage caused by asparaginase, a common chemotherapy drug that often affects the liver, especially in certain groups. People newly diagnosed with these cancers who have not had prior chemotherapy might be a good fit for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking ursodiol, you must stop it 7 days before meeting the laboratory criteria for the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that levocarnitine is generally safe for people. It is a natural substance produced by the body and found in many foods. Some studies have found that levocarnitine can help protect the liver, especially during chemotherapy. For instance, one study suggested that taking levocarnitine for 60 days improved liver enzyme levels, which indicate liver health.
In lab studies (not involving people), levocarnitine prevented liver damage from asparaginase, a common chemotherapy drug. This suggests it might reduce liver harm during treatment. Additionally, levocarnitine is already used to treat low carnitine levels in the body, which can otherwise lead to liver and other organ damage.
Overall, evidence suggests levocarnitine is well-tolerated and may help protect the liver during chemotherapy. However, it is always important to consult a healthcare provider before starting any new treatment or supplement.12345Why do researchers think this study treatment might be promising?
Levocarnitine is unique because it serves a protective role for the liver during chemotherapy, addressing a key concern for patients with leukemia and lymphoma. Unlike traditional chemotherapy drugs like pegaspargase, which focus on targeting cancer cells, levocarnitine aims to prevent liver damage caused by these treatments. It acts by potentially reducing conjugated hyperbilirubinemia, a condition that can result from chemotherapy, thus offering a safeguard for the liver without altering the standard cancer-fighting regimen. Researchers are excited about levocarnitine because it could enhance the safety of chemotherapy, allowing patients to receive effective cancer treatment with reduced risk of liver complications.
What evidence suggests that levocarnitine could be an effective treatment for liver protection in leukemia and lymphoma patients?
Research suggests that levocarnitine, which participants in this trial may receive, might help protect the liver during chemotherapy for leukemia and lymphoma. Studies have shown that levocarnitine could reduce liver damage caused by asparaginase, a common drug in these cancer treatments. As a natural nutrient used by the body for energy, insufficient levels of levocarnitine are linked to liver problems. Early findings also indicate that levocarnitine does not interfere with chemotherapy's effectiveness. These insights offer hope that levocarnitine can lower the risk of serious liver damage during treatment.12467
Who Is on the Research Team?
Etan Orgel
Principal Investigator
Children's Oncology Group
Are You a Good Fit for This Trial?
This trial is for young adults aged 15-39 with newly diagnosed B-ALL, T-ALL, lymphoblastic lymphoma, or MPAL. They must have liver function within certain limits and plan to receive asparaginase chemotherapy. Excluded are those with Down syndrome, inherited/autoimmune liver diseases, severe liver fibrosis, prior malignancy treatments (except specific allowed cases), pregnant or breastfeeding women, and those not using effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction
Patients receive induction chemotherapy with or without levocarnitine to assess its effect on liver toxicity
Rescue
Patients who develop conjugated hyperbilirubinemia may receive levocarnitine rescue treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Levocarnitine
Trial Overview
The study tests if Levocarnitine added to standard chemotherapy can protect the liver from damage caused by asparaginase in leukemia/lymphoma patients. It compares outcomes of patients receiving Levocarnitine plus chemotherapy against those receiving only standard chemo.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Patients in Arms A and B who develop conjugated hyperbilirubinemia \> 3 mg/dL during induction may receive levocarnitine rescue PO or IV as a bolus dose over 2 to 3 minutes or by infusion (over 10 to 30 minutes or per institutional standard) until resolution of conjugated hyperbilirubinemia =\< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first).
Patients receive levocarnitine PO or IV as a bolus over 2 to 3 minutes or by infusion (over 10 to 30 minutes or per institutional standard) starting prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol and continued through the earlier of the last day of Induction phase (i.e., day prior to start of next phase) or Induction day 35. Patients may also undergo blood sample collection during screening and on study.
Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Oncology Group
Lead Sponsor
Citations
NCT05602194 | Studying the Effect of Levocarnitine in ...
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver ...
Studying the Effect of Levocarnitine in Protecting the Liver ...
The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver ...
Levocarnitine does not impair chemotherapy cytotoxicity ...
Together, our findings show that LC supplementation is a safe strategy to prevent/reverse ASNase-induced toxicities in preclinical models. Keywords: Acute ...
Levocarnitine to Reduce Hepatotoxicity in Patients with ...
This early phase I trial tests the safety, side effects, and effectiveness of levocarnitine given during induction and consolidation therapy for patients ...
Studying the Effect of Levocarnitine in Protecting the Liver ...
The purpose of this study is to compare the effect of adding levocarnitine to standard chemotherapy vs. standard chemotherapy alone in ...
Effects of oral Lcarnitine supplementation on liver enzymes in ...
The results of this study suggested that a 60-day Lcarnitine treatment can improve liver enzyme levels and thus prevent the extent of liver damage during the ...
L-Carnitine - Uses, Side Effects, and More
Toxicity caused by valproic acid seems to be linked with L-carnitine deficiency. Taking L-carnitine by mouth or by IV can prevent liver toxicity from valproic ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.